N/A
N=78
Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes
Idiopathic Macular Hole
Bottom Line
View on ClinicalTrials.gov: NCT00302328 ↗Enrolled (actual)
78
Serious AEs
24.4%
Results posted
Apr 2014
Primary outcome: Primary: Visual Acuity (ETDRS Letters) — 74.9; 72.4; 72.2 Visual acuity in letters
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- macular hole operation (Procedure)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Glostrup University Hospital, Copenhagen
- Primary completion
- Jan 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Visual Acuity (ETDRS Letters) |
74.9; 72.4; 72.2 | — |
| SECONDARY Anatomic Success |
11; 32; 16 | — |
| SECONDARY Visual Field Defects |
0; 1; 1 | — |
Summary
The project is a randomized clinical trial with a follow up time of 12 months comparing the effects of surgical treatment of idiopathic macular holes. Patients are randomized to vitrectomy alone, vitrectomy plus indocyanine green (ICG) assisted inner limiting membrane ( ILM) peeling or vitrectomy plus trypan blue (tb) assisted ILM peeling. At baseline patients are characterized using early treatment diabetic retinopathy study (ETDRS) visual charts, tests of aniseikonia, optical coherence tomography 3 (OCT3), visual field and fundus photography. Per- and postoperative complications are registered.
Data analyses will help clarify the effect of ILM peeling on hole closure and visual acuity. Comparing results after ICG- and tb assisted ILM peeling will help clarify the topic of a toxic effect on retinal cells after staining and peeling of the ILM. Changes in intraretinal morphology before and after dye-assisted ILM peeling will be studied using OCT3 imaging and the patients' subjective opinion on the surgical results will be analyzed using quality of life questionnaires and metamorphopsia tests.
Eligibility Criteria
Inclusion Criteria
- Idiopathic macular hele stage 2 or 3.
- Duration of Symptoms ≤ 12 months.
- Visual acuity ≥ 34 ETDRS letters.
- Intraocular pressure ≤ 23 mmHg.
- Informed consent.
Exclusion Criteria
- Previous macular hole in project eye
- Macular pucker worse than a cellophane macular reflex.
- Previous surgery or disease in the eye affecting retinal function.
- Systemic disease affection vision including diabetes mellitus with level of retinopathy ≥ 14a.
- Amblyopia i project eye.
Data sourced from ClinicalTrials.gov (NCT00302328). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.